Do sodium‐glucose co‐transporter‐2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?-Reference-Cited by-同舟云学术

Do sodium‐glucose co‐transporter‐2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?

Published:2021-05-28 Issue:9 Volume:23 Page:2009-2019
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Kuhre Rune E.¹²^ORCID,Deacon Carolyn F.¹³^ORCID,Wewer Albrechtsen Nicolai J.¹⁴⁵^ORCID,Holst Jens J.¹⁶^ORCID

Affiliation:

1. Department of Biomedical Sciences, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

2. Obesity Pharmacology Novo Nordisk Måløv Denmark

3. School of Biomedical Sciences Ulster University Coleraine UK

4. Department of Clinical Biochemistry, Rigshospitalet University of Copenhagen Copenhagen Denmark

5. Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

6. Novo Nordisk Foundation Centre for Basic Metabolic Research, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

Funder

Lundbeckfonden

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14422

Reference89 articles.

1. SGLT2-INHIBITORS: A NOVEL CLASS FOR THE TREATMENT OF TYPE 2 DIABETES INTRODUCTION OF SGLT2-INHIBITORS IN CLINICAL PRACTICE

2. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

3. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials

4. Ipragliflozin: First Global Approval

5. Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SGLT2 inhibitors and AMPK: The road to cellular housekeeping?;Cell Biochemistry and Function;2024-01

2. SGLT2 Inhibitors and Safety in Older Patients;Heart Failure Clinics;2022-10

3. Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages;International Journal of Molecular Sciences;2021-10-25